F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies, where the second binding site is in the constant Fc region of an antibody, offering unprecedented ease in the discovery, development and manufacturing of bispecific antibody products. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including, AbbVie, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim.
Type
Private
HQ
Cambridgeshire, GB
Founded
2006
Size (employees)
81 (est)-2%
Website
f-star.com
F-star Biotechnology was founded in 2006 and is headquartered in Cambridgeshire, GB
Report incorrect company information

Key People/Management at F-star Biotechnology

John Haurum

John Haurum

CEO
Jane Dancer

Jane Dancer

Chief Business Officer
Tolga Hassan

Tolga Hassan

CFO
Neil Brewis

Neil Brewis

Chief Scientific Officer
Mihriban Tuna

Mihriban Tuna

Vice President, Drug Discovery
Mike Davies

Mike Davies

Vice President, Protein Science
Show more

F-star Biotechnology Office Locations

F-star Biotechnology has offices in Cambridgeshire and Wien
Wien, AT
7 Schwarzenbergpl.
Show all (2)
Report incorrect company information

F-star Biotechnology Financials and Metrics

Summary Metrics

Founding Date

2006

Total Funding

$57.3 m

Latest funding size

$9.40 m

Time since last funding

5 years ago

Investors

F-star Biotechnology's latest funding round in October 2013 was reported to be $9.4 m. In total, F-star Biotechnology has raised $57.3 m
Show all financial metrics

F-star Biotechnology Financials

F-star Biotechnology's revenue was reported to be £13.85 m in FY, 2016
GBP

Revenue (FY, 2016)

13.9 m

Net income (FY, 2016)

(1.2 m)

Cash (31-Dec-2016)

1.1 m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

405.2 k2.4 m7.1 m7.7 m13.9 m

Revenue growth, %

196%8%

Pre tax profit

(1.2 m)(3.3 m)825.7 k(797.2 k)(1.5 m)

Income tax expense

132.5 k460.2 k6 k(20.1 k)397.8 k
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.3 m1.2 m240.8 k1.3 m1.1 m

Accounts Receivable

405.2 k752.5 k65.2 k

Current Assets

3 m2.6 m2.8 m6.1 m4.3 m

PP&E

463 k400.6 k491.7 k946.7 k1.4 m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(1.1 m)(2.8 m)831.7 k(817.3 k)(1.2 m)

Cash From Operating Activities

(1.2 m)(887.6 k)(211.3 k)(1.4 m)299.1 k

Cash From Financing Activities

3.5 m(142.6 k)(443.3 k)4.6 m(145.5 k)

Net Change in Cash

2.3 m(1.1 m)(925.6 k)1 m(200.5 k)
GBPY, 2016

Revenue/Employee

227.8 k

Financial Leverage

-11.5 x
Show all financial metrics
Report incorrect company information

F-star Biotechnology Online and Social Media Presence

Embed Graph
Report incorrect company information